foscarnet has been researched along with Recrudescence in 65 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 9.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 9.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 9.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 8.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 7.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "A leukemic child developed recurrent herpes simplex virus lesions shortly after receiving a bone marrow transplant and while taking acyclovir." | 7.71 | Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. ( Bryant, P; Carapetis, J; Curtis, N; Sasadeusz, J; Waters, K, 2001) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 7.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 7.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 7.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 7.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "A 41-year-old recipient of matched unrelated BMT acquired a severe mucocutaneous herpes simplex virus (HSV) type I infection during acyclovir prophylaxis." | 7.68 | Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. ( Cornelissen, JJ; de Gast, GC; Dekker, AW; Lepoutre, J; Rozenberg-Arska, M; Smit, J; Verdonck, LF, 1993) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 6.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 6.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 5.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 5.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 5.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "Clinic-initiated topical treatment of recurrent genital herpes with foscarnet cream (concentration, 0." | 5.06 | Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial. ( Aoki, FY; Bright, C; Kaluski, J; Lawee, D; Poisson, M; Portnoy, J; Sacks, SL; Schlech, W; Tyrrell, DL, 1987) |
| "A double blind, placebo controlled trial was performed in nine sexually transmitted diseases (STD) clinics in the United Kingdom and the Netherlands to investigate the efficacy of trisodium phosphonoformate (foscarnet) cream in treating recurrent genital herpes simplex virus (HSV) infection." | 5.06 | Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study. ( Barton, SE; Essex-Cater, AJ; Kinghorn, GR; Kuijpers, MH; Munday, PE; Notowicz, A; Rashid, S; Schuller, JL; Stolz, E; van der Meijden, WI, 1986) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 4.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation." | 3.79 | The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. ( Cunha-Bang, Cd; Frederiksen, CM; Gustafsson, F; Iversen, M; Kirkby, N; Kjaer, J; Lepri, AC; Lundgren, JD; Rasmussen, A; Sengeløv, H; Sønderholm, M; Sørensen, SS, 2013) |
| "A leukemic child developed recurrent herpes simplex virus lesions shortly after receiving a bone marrow transplant and while taking acyclovir." | 3.71 | Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child. ( Bryant, P; Carapetis, J; Curtis, N; Sasadeusz, J; Waters, K, 2001) |
| "The objective of this study was to investigate the prevalence of resistance of herpes simplex virus to acyclovir and foscarnet." | 3.71 | [In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?]. ( Cañizares, A; Guerrero, A; Hellín, T; Losada, I; Martí-Belda, P, 2002) |
| " Cytomegalovirus prophylaxis consisted of acyclovir for SIBs and foscarnet for MUDs." | 3.69 | Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. ( Bacigalupo, A; Barbanti, M; Corvo, R; Delfino, L; Ferrara, GB; Ficai, G; Frassoni, F; Ghinatti, C; Gualandi, F; Lamparelli, T; Morabito, A; Occhini, D; Pozzi, S; Sacchi, N; Van Lint, MT; Vitale, V; Zikos, P, 1997) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 3.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 3.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 3.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "A 41-year-old recipient of matched unrelated BMT acquired a severe mucocutaneous herpes simplex virus (HSV) type I infection during acyclovir prophylaxis." | 3.68 | Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. ( Cornelissen, JJ; de Gast, GC; Dekker, AW; Lepoutre, J; Rozenberg-Arska, M; Smit, J; Verdonck, LF, 1993) |
| "The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1)." | 3.67 | Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. ( Datema, R; Ericson, AC; Kristofferson, A; Sohl-Akerlund, A, 1988) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 2.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| " No significant difference in the incidence of local or systemic adverse effects was noted between the two groups." | 2.66 | Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study. ( Aoki, FY; Lawee, D; Portnoy, J; Rosenthal, D, 1988) |
| "Foscarnet treated men with subpreputial lesions had a shorter period of ulcers (1." | 2.66 | Topical treatment of recurrent genital herpes infections with foscarnet. ( Lernestedt, JO; Lycke, E; Ogenstad, S; Wallin, J, 1985) |
| "The median number of recurrences up to the observation of foveal-sparing retinitis was two (range one to eight), and five patients had active CMV retinitis despite treatment for at least two continuous months." | 2.39 | A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. ( Ai, E; Luckie, AP, 1996) |
| "The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem." | 2.36 | [Herpes simplex]. ( Fanta, D, 1981) |
| "Bilateral recurrence of CMV retinitis occurred on day 89 of life, requiring a second course of intravitreal foscarnet injections and intravenous ganciclovir." | 1.40 | Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant. ( Baumal, CR; Tawse, KL, 2014) |
| "A 10-year-old girl with M2 acute myeloid leukemia underwent an unrelated cord blood transplantation in refractory first relapse." | 1.31 | Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation. ( Cañete, A; Carvajal, E; Castel, V; Fernández, JM; Verdeguer, A, 2001) |
| "A mild recurrence developed in one eye when ganciclovir and foscarnet were both tapered to a single daily dose." | 1.30 | The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy. ( Ciulla, TA; Duker, JS; Morley, MG; Rutledge, BK, 1998) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 1.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "Among the atypical forms of chronic varicella, this eruption appears to be unique." | 1.29 | Chronic varicella presenting as disseminated pinpoint-sized papules in a man infected with the human immunodeficiency virus. ( Castanet, J; Durant, J; Lacour, JP; Ortonne, JP; Perrin, C; Rodot, S; Van Elslande, L, 1996) |
| "Recurrences were recognized as increased retinal opacification at the borders of preexisting lesions or as new lesions." | 1.29 | Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome. ( Engstrom, RE; Holland, GN; Johnston, WH; Rimmer, S, 1993) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 1.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Forty-four percent remained free of recurrences until they died (for up to 15 months); 56% had 1 to 4 recurrences, altogether 35 episodes, of which 14 occurred after withdrawal of therapy." | 1.28 | [Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy]. ( Fabricius, EM; Popescu, M; Schmitz, K, 1992) |
| "Among 347 AIDS patients seen at St Mary's Hospital, London between 1983 and 1989, cytomegalovirus (CMV) disease was observed in 75 (22%)." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (10.77) | 18.7374 |
| 1990's | 40 (61.54) | 18.2507 |
| 2000's | 10 (15.38) | 29.6817 |
| 2010's | 8 (12.31) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pushkarevskaya, A | 1 |
| Bidier, M | 1 |
| Hartmann, M | 1 |
| Enk, A | 1 |
| Hadaschik, E | 1 |
| Danziger-Isakov, L | 1 |
| Englund, J | 1 |
| Green, M | 1 |
| Posfay-Barbe, KM | 1 |
| Zerr, DM | 1 |
| Tawse, KL | 1 |
| Baumal, CR | 1 |
| Boss, JD | 1 |
| Rosenberg, K | 1 |
| Shah, R | 1 |
| Rosen, T | 1 |
| Travi, G | 1 |
| Pergam, SA | 1 |
| Xie, H | 1 |
| Boeckh, MJ | 1 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Kobayashi, R | 1 |
| Takanashi, K | 1 |
| Suzuki, D | 1 |
| Nasu, T | 1 |
| Uetake, K | 1 |
| Matsumoto, Y | 1 |
| Cunha-Bang, Cd | 1 |
| Kirkby, N | 1 |
| Sønderholm, M | 1 |
| Sørensen, SS | 1 |
| Sengeløv, H | 1 |
| Iversen, M | 1 |
| Rasmussen, A | 1 |
| Gustafsson, F | 1 |
| Frederiksen, CM | 1 |
| Kjaer, J | 1 |
| Lepri, AC | 1 |
| Lundgren, JD | 1 |
| Aoyama, Y | 1 |
| Yamamura, R | 1 |
| Shima, E | 1 |
| Nakamae, H | 1 |
| Makita, K | 1 |
| Hasegawa, T | 1 |
| Sakamoto, C | 1 |
| Terada, Y | 1 |
| Kho, G | 1 |
| Ohta, K | 1 |
| Yamane, T | 1 |
| Takubo, T | 1 |
| Hino, M | 1 |
| de Schryver, I | 1 |
| Rozenberg, F | 1 |
| Cassoux, N | 1 |
| Michelson, S | 1 |
| Kestelyn, P | 1 |
| Lehoang, P | 1 |
| Davis, JL | 1 |
| Bodaghi, B | 1 |
| Fanta, D | 1 |
| Singh, N | 1 |
| Gayowski, T | 1 |
| Balfour, HH | 2 |
| Wilcox, CM | 1 |
| Straub, RF | 1 |
| Schwartz, DA | 1 |
| Colebunders, R | 1 |
| Van den Abbeele, K | 1 |
| Fleerackers, Y | 1 |
| Bols, K | 1 |
| Lachenal, M | 1 |
| Van Damme, L | 1 |
| Benson, C | 1 |
| Braun, J | 1 |
| Cassens, B | 1 |
| Erice, A | 1 |
| Friedman-Kien, A | 1 |
| Klein, T | 1 |
| Polsky, B | 1 |
| Safrin, S | 2 |
| Diaz-Llopis, M | 1 |
| España, E | 1 |
| Muñoz, G | 1 |
| Navea, A | 1 |
| Chipont, E | 1 |
| Cano, J | 1 |
| Menezo, JL | 1 |
| Romero, FJ | 1 |
| Weinberg, DV | 1 |
| Murphy, R | 1 |
| Naughton, K | 1 |
| Leport, C | 1 |
| Puget, S | 1 |
| Pepin, JM | 1 |
| Levy, S | 1 |
| Perronne, C | 1 |
| Brun-Vezinet, F | 1 |
| Vildé, JL | 1 |
| Johnston, WH | 1 |
| Holland, GN | 1 |
| Engstrom, RE | 1 |
| Rimmer, S | 1 |
| Verdonck, LF | 1 |
| Cornelissen, JJ | 1 |
| Smit, J | 1 |
| Lepoutre, J | 1 |
| de Gast, GC | 1 |
| Dekker, AW | 1 |
| Rozenberg-Arska, M | 1 |
| Young, LH | 1 |
| Desatnik, HR | 1 |
| Foster, RE | 2 |
| Lowder, CY | 2 |
| Dodds, EM | 1 |
| Avery, RK | 1 |
| Prayson, RA | 1 |
| Hardy, D | 1 |
| Luckie, AP | 1 |
| Ai, E | 1 |
| Castanet, J | 1 |
| Rodot, S | 1 |
| Lacour, JP | 1 |
| Van Elslande, L | 1 |
| Perrin, C | 1 |
| Durant, J | 1 |
| Ortonne, JP | 1 |
| Kuppermann, BD | 1 |
| Walton, RC | 1 |
| Whitcup, SM | 1 |
| Mueller, BU | 1 |
| Lewis, LL | 1 |
| Pizzo, PA | 1 |
| Nussenblatt, RB | 1 |
| Katlama, C | 1 |
| Beasley, KL | 1 |
| Cooley, GE | 1 |
| Kao, GF | 1 |
| Lowitt, MH | 1 |
| Burnett, JW | 1 |
| Aurelian, L | 1 |
| Lamparelli, T | 1 |
| Van Lint, MT | 1 |
| Gualandi, F | 1 |
| Occhini, D | 1 |
| Barbanti, M | 1 |
| Sacchi, N | 1 |
| Ficai, G | 1 |
| Ghinatti, C | 1 |
| Ferrara, GB | 1 |
| Delfino, L | 1 |
| Pozzi, S | 1 |
| Morabito, A | 1 |
| Zikos, P | 1 |
| Vitale, V | 1 |
| Corvo, R | 1 |
| Frassoni, F | 1 |
| Bacigalupo, A | 1 |
| Goodgame, RW | 1 |
| Scoular, A | 1 |
| Barton, S | 1 |
| Tural, C | 1 |
| Romeu, J | 1 |
| Sirera, G | 1 |
| Andreu, D | 1 |
| Conejero, M | 1 |
| Ruiz, S | 1 |
| Jou, A | 1 |
| Bonjoch, A | 1 |
| Ruiz, L | 1 |
| Arnó, A | 1 |
| Clotet, B | 1 |
| Ciulla, TA | 1 |
| Rutledge, BK | 1 |
| Morley, MG | 1 |
| Duker, JS | 1 |
| Schürmann, D | 1 |
| Bergmann, F | 1 |
| Grobusch, MP | 1 |
| Behnsch, M | 1 |
| Liekfeld, A | 1 |
| Awan, AR | 1 |
| Harmenberg, J | 1 |
| Kristofferson, A | 2 |
| Field, HJ | 1 |
| Cherrington, JM | 1 |
| Fuller, MD | 1 |
| Lamy, PD | 1 |
| Miner, R | 1 |
| Lalezari, JP | 1 |
| Nuessle, S | 1 |
| Drew, WL | 1 |
| Fabricius, EM | 2 |
| Bini, EJ | 1 |
| Gorelick, SM | 1 |
| Weinshel, EH | 1 |
| Castagnola, E | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Cristina, E | 1 |
| Chierici, M | 1 |
| Lanino, E | 1 |
| Bryant, P | 1 |
| Sasadeusz, J | 1 |
| Carapetis, J | 1 |
| Waters, K | 1 |
| Curtis, N | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Losada, I | 1 |
| Cañizares, A | 1 |
| Hellín, T | 1 |
| Martí-Belda, P | 1 |
| Guerrero, A | 1 |
| Aoki, FY | 3 |
| Carvajal, E | 1 |
| Verdeguer, A | 1 |
| Fernández, JM | 1 |
| Cañete, A | 1 |
| Castel, V | 1 |
| Jabs, DA | 1 |
| Birch, CJ | 1 |
| Tyssen, DP | 1 |
| Tachedjian, G | 1 |
| Doherty, R | 1 |
| Hayes, K | 1 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Geier, SA | 1 |
| Klauss, V | 1 |
| Matuschke, A | 1 |
| Kronawitter, U | 1 |
| Goebel, FD | 1 |
| Schmitz, K | 1 |
| Popescu, M | 1 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Davis, R | 1 |
| Hafner, R | 1 |
| Rush, J | 1 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| Mills, J | 1 |
| Peters, BS | 1 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Main, J | 1 |
| Migdal, C | 2 |
| Harris, JR | 2 |
| Pinching, AJ | 1 |
| Coker, RJ | 1 |
| Tomlinson, D | 1 |
| Horner, P | 1 |
| Arbesfeld, DM | 1 |
| Thomas, I | 1 |
| Walmsley, SL | 1 |
| Chew, E | 1 |
| Read, SE | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Rachlis, A | 1 |
| Fanning, MM | 1 |
| Ericson, AC | 1 |
| Sohl-Akerlund, A | 1 |
| Datema, R | 1 |
| Barton, SE | 1 |
| Munday, PE | 1 |
| Kinghorn, GR | 1 |
| van der Meijden, WI | 1 |
| Stolz, E | 1 |
| Notowicz, A | 1 |
| Rashid, S | 1 |
| Schuller, JL | 1 |
| Essex-Cater, AJ | 1 |
| Kuijpers, MH | 1 |
| Sacks, SL | 1 |
| Portnoy, J | 2 |
| Lawee, D | 2 |
| Schlech, W | 1 |
| Tyrrell, DL | 1 |
| Poisson, M | 1 |
| Bright, C | 1 |
| Kaluski, J | 1 |
| Rosenthal, D | 1 |
| Wallin, J | 1 |
| Lernestedt, JO | 1 |
| Ogenstad, S | 1 |
| Lycke, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002272] | 0 participants | Interventional | Completed | ||||
| An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002021] | 0 participants | Interventional | Completed | ||||
| Cytomegalovirus Retinitis Retreatment Trial[NCT00000134] | Phase 3 | 279 participants (Actual) | Interventional | 1992-12-31 | Completed | ||
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. (NCT00000134)
Timeframe: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
| Intervention | participants (Number) |
|---|---|
| Intravenous Foscarnet | 88 |
| Intravenous Ganciclovir | 93 |
| Combination Therapy | 93 |
8 reviews available for foscarnet and Recrudescence
| Article | Year |
|---|---|
[Herpes simplex].
Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe | 1981 |
Cytomegalovirus retinitis in persons with AIDS. Selecting therapy for a sight-threatening disease.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans; Mu | 1995 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1996 |
Therapeutic options for resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus | 1997 |
Management of CMV retinitis in HIV infected patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytome | 1997 |
Management of genital herpes in HIV-infected patients.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral A | 2001 |
Cutaneous herpes simplex virus infections.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Drug Resistance, Microbi | 1991 |
8 trials available for foscarnet and Recrudescence
| Article | Year |
|---|---|
High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Female; Foscarnet; Humans; | 1994 |
Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 1996 |
Foscarnet eyedrops in recurrence prophylaxis of herpes simplex virus keratitis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Female; Foscarnet; Humans; Keratitis, Herpetic; Ma | 1998 |
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.
Topics: Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Female; Foscarnet; Herpes Ge | 1986 |
Clinical course of recurrent genital herpes and treatment with foscarnet cream: results of a Canadian multicenter trial.
Topics: Administration, Topical; Adolescent; Adult; Antiviral Agents; Clinical Trials as Topic; Double-Blind | 1987 |
Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiviral Agents; Clinical Trials as Topic; Double | 1988 |
Topical treatment of recurrent genital herpes infections with foscarnet.
Topics: Administration, Topical; Adult; Clinical Trials as Topic; Double-Blind Method; Erythema; Female; Fos | 1985 |
49 other studies available for foscarnet and Recrudescence
| Article | Year |
|---|---|
Viral reactivation imitates relapse of pemphigus vulgaris in an immunosuppressed patient.
Topics: Autoantibodies; Combined Modality Therapy; Cytomegalovirus; Debridement; Desmoglein 1; Desmoglein 3; | 2017 |
Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges.
Topics: Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Fatal | 2018 |
Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Female; Foscarnet; Ganciclovir; Gestational Age; Humans | 2014 |
Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Viral; Drug Therapy, | 2016 |
Recurrent Herpes Labialis in Adults: New Tricks for an Old Dog.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Adult; Antiviral Agents; Chronic Disease; | 2017 |
Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Topics: Acyclovir; Adolescent; Adult; Antibodies, Viral; Antigens, Viral; Antiviral Agents; Child; Child, Pr | 2009 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Child; Cytomegalovirus Retinitis; Drug Therapy, C | 2012 |
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection.
Topics: Adult; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganci | 2013 |
[Successful treatment with foscarnet for disseminated varicella-zoster infection after reduced intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma].
Topics: Acyclovir; Adult; Antiviral Agents; Central Nervous System Neoplasms; Drug Resistance, Viral; Foscar | 2003 |
Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Chronic Disease; Cytomegalovirus; Cyto | 2006 |
Lack of sustained efficacy of combination ganciclovir and foscarnet for hepatitis B virus recurrence after liver transplantation.
Topics: Drug Therapy, Combination; Foscarnet; Ganciclovir; Hepatitis B; Humans; Liver Transplantation; Male; | 1995 |
Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Administration Schedu | 1995 |
Two AIDS patients with life-threatening pancreatitis successfully treated, one with ganciclovir the other with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Female; Foscarnet; Gancicl | 1994 |
Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedul | 1994 |
Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus.
Topics: Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Microbial; Foscarnet; Ganciclovir; HIV | 1993 |
Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome.
Topics: Acyclovir; Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Foscarnet; Fundus Ocu | 1993 |
Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT.
Topics: Acyclovir; Adult; Animals; Bone Marrow Transplantation; Chlorocebus aethiops; Esophagitis; Foscarnet | 1993 |
Therapy for cytomegalovirus retinitis: still no silver lining.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1996 |
Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Ret | 1996 |
Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomega | 1996 |
Current management of cytomegalovirus infection: treatment and prophylaxis.
Topics: Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Reti | 1996 |
Chronic varicella presenting as disseminated pinpoint-sized papules in a man infected with the human immunodeficiency virus.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chickenpox; Chronic Disea | 1996 |
Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus Re | 1995 |
Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency.
Topics: Acyclovir; Adult; Biopsy; Common Variable Immunodeficiency; Drug Resistance, Microbial; Female; Feta | 1997 |
Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Topics: Acyclovir; Adolescent; Adult; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cause | 1997 |
How to treat the cytomegalovirus troll.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; DNA, Viral; Fos | 1998 |
Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, | 1997 |
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus | 1998 |
The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis | 1998 |
Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cidofovir; Cytomegalovirus Retinitis; | 1998 |
Herpes simplex virus zosteriform lesions with adoptive transfer of immune cells: a murine model which mimics human recurrent disease.
Topics: Administration, Topical; Adoptive Transfer; Animals; Antiviral Agents; Cell Line; Cricetinae; Diseas | 1998 |
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, | 1998 |
Outcome of AIDS-associated cytomegalovirus colitis in the era of potent antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Cytomegalov | 2000 |
Two-drug treatment effective against recurrent CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1996 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Successful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous cidofovir in a child.
Topics: Acyclovir; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytosine; Drug Resistanc | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
[In vitro susceptibility study of herpes simplex virus to acyclovir and foscarnet. Are routine susceptibility studies necessary?].
Topics: Acyclovir; Antiviral Agents; Diagnostic Tests, Routine; Drug Resistance, Viral; Foscarnet; Herpes Si | 2002 |
Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Child; Combined Modality Therapy; | 2001 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cataract Extraction; Cytomegalovirus Infections; Drug Adminis | 1992 |
[Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; L | 1992 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Adult; Cytomegalovirus Infections; Drug Combinations; Foscarnet; Ganciclovir; HIV Seropositivity; Hu | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Topics: Acyclovir; Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Disease Models, | 1988 |